Corporate Banner
Satellite Banner
Technology Networks Header
Friday, August 22, 2014
Technology Networks
 
Register | Sign in
Home Page>Products
  Product News
Integrated DNA Technologies Advances Human Health and Clinical Research
Monday, March 24, 2014
Company extends its portfolio of NGS panels with the addition of the xGen® Inherited Disease and Pan-Cancer Panels.

QIAGEN Expands GeneGlobe Web Portal
Tuesday, March 11, 2014
Portal now includes interactive access to extensive genomic content from Ingenuity’s Knowledge Base.

WuXi PharmaTech Purchases an Illumina HiSeq X Ten Sequencing System
Tuesday, March 11, 2014
New investment will enable WuXi's services to expand to population genome scale sequencing.

Swift Biosciences Launches Accel-NGS™ 2S DNA Library Kit
Monday, March 10, 2014
Product dramatically reduces sample requirements for NGS sample prep.

ShrimpEX Adopts DNASTAR Lasergene Software
Wednesday, March 05, 2014
Site license provides both the software and the support to ShrimpEX.

Genetically Characterized FFPE Tissue Samples
Tuesday, February 25, 2014
CancerSeq™ - New range of tissue samples from AMSBIO.

Automated TruSeq® Stranded Total RNA Library Preparation Method
Tuesday, February 25, 2014
Stranded Total RNA sequencing library preparation using epMotion minimizes hands-on time.

Pathway Genomics Launches Hereditary Colorectal Cancer Genetic Test
Thursday, February 20, 2014
Test uses NGS technology to identify gene alterations or mutations.

Bioo Scientific Launches NEXTflex™ Dual-Indexed DNA Barcodes
Thursday, February 20, 2014
Barcodes to further increase NGS throughput.

<< 1 2 3 4 5 6 7 >>
Showing Results 31 - 40 of 200
Scientific News
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Shenogen and Chemizon Announce Drug Discovery Collaboration Focused on Oncology and Endocrine Disorders
The agreement will create small molecule therapeutics targeting modulators of the ER-alpha 36 receptor.
Dutch Public-Private Partnership Invests 28 Million Euro on Research into Personalized Medicine
The Netherlands' three Top Institutes for life-science research announce a joint research target to bring personalized medicine closer to reality.
FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of DGF in Kidney Transplant Patients
Company completes enrollment and dosing in the dose-escalation safety portion of a Phase 1/2 study.
Oncolytics Biotech® Receives MHRA Approval to Conduct Phase 3 Trial for REOLYSIN®
Conducting the trials in U.S. and Europe will allow Company to access the physicians that have worked with REOLYSIN in head and neck cancers.
Skyscraper Banner
Skyscraper Banner
Follow TechNetcom1 on Twitter
Technology Networks Ltd. on LinkedIn
Go to LabTube.tv